Wyeth

Vtv Therapeutics LLC

Transtech Pharma, Inc.

Eric Joel Benjamin

Kai Zhuang

Adnan M M Mjalli

Dharma Rao Polisetti

Thorsteinn Thorsteinsson

Wendy Ann Dulin

Yanning Lin

Muhammad Ashraf

Ashwinkumar Jain

Robert Rothlein

Ye Edward Tian

Hassan El Abdellaoui

Jeffrey C Webster

Soumya P Sahoo

Danilo Almariego

Jiwaji Gulabrao Suryawanshi

Siva Kumar Rapuru

The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.

Sustained release pharmaceutical compositions

The invention provides tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist. The invention further provides solid compositions comprising tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist. The invention further provides uses of tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist, e.g., for treating type 1 diabetes, type 2 diabetes, or obesity.

Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereof

Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin C2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.

RAGE fusion proteins, formulations, and methods of use thereof

This invention relates to novel pharmaceutical carrier or excipient systems and oral pharmaceutical compositions comprising 1-[4-(2-Azepan-1yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol or 2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)benzyl]-1H-indol-5-ol, or a pharmaceutically acceptable salt thereof.

Pharmaceutical compositions of estrogenic agents

The present invention provides an amorphous form of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid. This invention also provides processes for preparing the amorphous form and pharmaceutical compositions including the amorphous form.

Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions

Growing community of inventors

Jamestown, NC, United States of America

Eric Joel Benjamin